while the 36-month beta value is 2.63.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
The average price point forecasted by analysts for Seres Therapeutics Inc. (MCRB) is $10.43, which is $6.33 above the current market price. The public float for MCRB is 116.29M, and currently, short sellers hold a 12.91% ratio of that floaft. The average trading volume of MCRB on May 26, 2023 was 2.90M shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
MCRB) stock’s latest price update
Seres Therapeutics Inc. (NASDAQ: MCRB) has seen a decline in its stock price by -4.11 in relation to its previous close of 4.87. However, the company has experienced a -3.11% decline in its stock price over the last five trading sessions.
MCRB’s Market Performance
MCRB’s stock has fallen by -3.11% in the past week, with a monthly drop of -27.03% and a quarterly drop of -6.41%. The volatility ratio for the week is 5.12% while the volatility levels for the last 30 days are 8.82% for Seres Therapeutics Inc. The simple moving average for the last 20 days is -9.49% for MCRB stock, with a simple moving average of -21.35% for the last 200 days.
MCRB Trading at -16.50% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.79% of loss for the given period.
Volatility was left at 8.82%, however, over the last 30 days, the volatility rate increased by 5.12%, as shares sank -12.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.48% lower at present.
During the last 5 trading sessions, MCRB fell by -3.11%, which changed the moving average for the period of 200-days by -3.11% in comparison to the 20-day moving average, which settled at $5.13. In addition, Seres Therapeutics Inc. saw -16.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from Ege David S., who sale 7,038 shares at the price of $5.19 back on Apr 28. After this action, Ege David S. now owns 59,696 shares of Seres Therapeutics Inc., valued at $36,527 using the latest closing price.
Ege David S., the of Seres Therapeutics Inc., sale 5,012 shares at $7.93 during a trade that took place back on Oct 31, which means that Ege David S. is holding 46,734 shares at $39,745 based on the most recent closing price.
Stock Fundamentals for MCRB
Current profitability levels for the company are sitting at:
- -45.70 for the present operating margin
The net margin for Seres Therapeutics Inc. stands at -45.25. The total capital return value is set at -33.43, while invested capital returns managed to touch -34.15.
Based on Seres Therapeutics Inc. (MCRB), the company’s capital structure generated 37.42 points at debt to equity in total, while total debt to capital is 27.23. Total debt to assets is 13.87, with long-term debt to equity ratio resting at 32.39. Finally, the long-term debt to capital ratio is 23.57.
When we switch over and look at the enterprise to sales, we see a ratio of 118.16, with the company’s debt to enterprise value settled at 0.09. The receivables turnover for the company is 30.88 and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.69.
Conclusion
In a nutshell, Seres Therapeutics Inc. (MCRB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
